Non-Hispanic black (NHB) women are more likely to experience an endometrial carcinoma (EC) recurrence compared to nonHispanic white (NHW) women. The extent to which tumor characteristics, socioeconomic status (SES) and treatment contribute to this observation is not well defined. In the NRG Oncology/Gynecology Oncology Group (GOG) 210 Study we evaluated associations between race/ethnicity and EC recurrence according to tumor characteristics with adjustment for potential confounders. Our analysis included 3,199 NHW, 532 NHB and 232 Hispanic women with EC. Recurrence was documented during followup. We used Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between race/ ethnicity and EC recurrence in models stratified by histologic subtype (low-grade endometrioid, high-grade endometrioid, serous, mixed cell, carcinosarcoma, clear cell) or stage (I, II, III) and adjusted for age, SES, body mass index, smoking status and treatment. In histologic subtype-stratified models, higher EC recurrence was noted in NHB women with low-grade endometrioid (HR 5 1.94, 95% CI 5 1.21-3.10) or carcinosarcomas (HR 5 1.66, 95% CI 5 0.99-2.79) compared to NHWs. In stagestratified models, higher EC recurrence was noted among NHB women with stage I (HR 5 1.48, 95% CI 5 1.06-2.05) and Key words: uterus neoplasm, racial disparities, outcomes, socioeconomic status, tumor heterogeneity Conflict of interest: Dr Cohn reported serving in an advisory/consulting role for Oncology Analytics; Dr Mutch reported serving in an advisory/consulting role for Lilly and paid to participate in a speakers' bureau for AstraZeneca; Dr Thaker reported serving in an advisory/consulting role for Celsion and received funding from Merck; Dr Moore has received research funding from Angle, Inc., and Fujirebio Diagnostics; Dr Lele reported serving in an advisory/consulting role and receiving honoraria from Genetech; Dr Guntupalli reported serving in an advisory/consulting role and receiving honoraria from Genentech and Janssen and receiving funding from Bristol-Myers Squibb and Dr Pearl receives royalties from our research foundation on behalf of VitaTex. This work has nothing to do with this research article or GOG 210 in general. 
Introduction
Endometrial carcinoma (EC) recurs in 2-15% of women with early stage disease and this proportion can reach as high as 50% in women with advanced stage or non-endometrioid histologic subtypes. 1 Recurrence contributes to worse survival, 1 and compared to white women, black women are more likely to experience an EC recurrence. 2 This observation has been attributed to a higher prevalence of adverse tumor characteristics, receipt of less aggressive treatment 3 and lower socioeconomic status (SES) 4 among black vs. white women. Adjustment for tumor characteristics attenuates associations between race and EC recurrence in some studies 5, 6 but not others. [7] [8] [9] Adding to this unclear picture is heterogeneous study populations and lack of adjustment for factors associated with EC recurrence. Furthermore, the literature is hindered by relatively low numbers of black women with EC, ranging from 14 to 257 black EC cases, limiting our understanding of the race-EC recurrence relationship. Finally, studies have not examined recurrence risk among Hispanic women, a growing demographic in the United States.
To clarify the effects of race and ethnicity on EC recurrence, we examined this relationship according to clinically relevant tumor characteristics in the NRG Oncology/Gynecologic Oncology Group (GOG) 210 Study, an observational study that included a large number of women with rare, aggressive endometrial tumors. We also assessed the hypothesis that SES mediates the association between race/ethnicity and EC recurrence. In addition to inclusion of diverse histologic subtypes, our study has the advantage of carefully collected epidemiological information and clinical outcomes along with a central pathology review of tumor characteristics.
Methods

Study population
Full details regarding the NRG Oncology/GOG 210 Study design have been published elsewhere. 10 Briefly, the NRG Oncology/GOG 210 Study was conducted from September 22, 2003 to December 1, 2011 at 62 U.S. institutions. Prior to surgery (hysterectomy, bilateral salpingo-oophorectomy and lymph node sampling at the discretion of the treating provider), consenting patients completed a self-administered questionnaire that collected demographic and epidemiologic information. 11 Of 6,124 women enrolled, 632 (10%) did not complete questionnaires and were excluded from further analyses. We excluded women for the following reasons: incomplete surgical staging (n 5 20), final diagnosis not EC (n 5 53), benign diagnoses (n 5 6), diagnosis of a second primary (n 5 2), misclassified pathologic diagnosis based on central pathology review (n 5 49), inadequate material for pathology review (n 5 22), protocol deviations (n 5 17), improper pre-protocol treatment (n 5 1), missing grade (n 5 23), mucinous tumors (n 5 18), unusual histologic types (including squamous cell, undifferentiated and dedifferentiated histologies) (n 5 111) and missing stage (n 5 5). We further excluded women with self-reported race/ ethnicity other than non-Hispanic black (NHB), nonHispanic white (NHW) or Hispanic [Asian (n 5 95), Native Hawaiian/Pacific Islander (n 5 12), American Indian (n 5 37), Other (n 5 46); N 5 231] and women with stage IV disease, as they are not free of disease following primary surgery and thus, not at risk of recurrence (n 5 236). Our analytic sample included 4,698 EC patients. Our study was approved by Institutional Review Boards at the National Cancer Institute and participating study centers. All participants provided informed consent prior to participation.
Risk factor assessment
Questionnaires assessed demographic characteristics (age, race, annual income, highest level education attained) and established EC risk factors, including height, weight, reproductive factors, diabetes, smoking status, oral contraceptive use, menopausal hormone use, tamoxifen use and history of breast cancer.
Tumor characteristics and outcome assessment
Pathology information was available from participating NRG Oncology/GOG institutions and through specialized reviews 11 What's new? Cancer of the endometrium (EC), the inner lining of the uterus, shows one of the most prominent racial disparities among common cancers with a 93% higher mortality rate in black as compared with white women. Here, the authors show that race also affects the recurrence rate of EC as non-Hispanic black and Hispanic women experience a higher cancer recurrence rate within certain subgroups defined by tumor characteristics such as low-grade endometrioid, carcinosarcoma and stages I and III tumors. The authors note that clinicians treating women with EC should be aware of racial differences in recurrence risk, particularly among women diagnosed with these specific tumor characteristics. 
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We used the Baron and Kenny approach 14 to determine the role of SES indicators (e.g., annual income and education) in mediating the relationship between race/ethnicity and EC recurrence in stratified models. In order for SES to mediate the relationship between race and EC recurrence, the following criteria are needed: (1) significant association between race/ethnicity and EC recurrence; (2) significant association between annual income/education and race and (3) significant association between annual income/education and EC recurrence in a model including race/ethnicity.
We performed several sensitivity analyses. First, to account for the possibility that deaths due to EC were due to undetected recurrences, we examined progression, or time to recurrence or EC death as the outcome. Second, we treated deaths from EC as competing events using the Fine-Gray model. 15 Third, as most EC recurrences occur within 3 years of diagnosis, we excluded women with follow-up time less than 1 year, 2 years and 3 years to account for the possibility that women did not have enough follow-up time to experience the outcome of interest. Finally, we compared associations between race/ethnicity and EC recurrence stratified by enrollment period (i.e., 2003-2007 vs. 2007-2011) . We tested the interaction by including a multiplicative interaction term between race/ethnicity and a binary variable indicating the enrollment period. Statistical analyses were performed using SAS (version 9.3, SAS Institute, Cary, NC) and Stata software (version 11, STATA Corp., College Station, TX). All p-values were two-sided.
Results
Of 4,698 study participants, the majority were NHW (n 5 3,911), followed by NHB (n 5 532), and Hispanic (any race, n 5 255). Distributions of epidemiological, tumor and treatment characteristics according to race/ethnicity are shown in Table 1 . Compared to NHB or NHW women, Hispanic women were significantly younger at EC diagnosis and more likely to: have less than high school education, have lower annual incomes, have older ages at menarche, be never smokers, be never users of oral contraceptives and be premenopausal. Compared to NHW or Hispanic women, NHB women were more likely to: be obese, be multiparous, have a history of diabetes and be non-users of menopausal hormones. As expected, NHB women more commonly had aggressive tumor characteristics, including positive pelvic and/or aortic lymph node involvement, positive peritoneal biopsy, advanced stage and histologic subtypes other than low-grade endometrioid compared to NHW and Hispanic women. Adjuvant chemotherapy, either with or without radiation, was more common among NHB (22%, 15%) than among Hispanic (16.5%, 10.2%) or NHW women (12.6%, 12.2%).
After a median follow-up of 5 years (range: 1 day-9.8 years), 753 recurrences occurred and 310 women died without a documented EC recurrence and were censored in the primary analysis. NHB women had higher EC recurrence risk overall (log-rank p < 0.001, data not shown), and among women with low-grade endometrioid (log-rank p 5 0.02) or carcinosarcoma (log-rank p 5 0.06) (Fig. 1) . In Kaplan-Meier plots stratified by stage, we observed worse EC recurrence among NHB women for stages I and II disease, while Hispanic women had worse EC recurrence among women with stage III disease (Fig. 2) . In the overall model NHB (HR 5 1.36, 95% CI 5 1.11-1.66, data not shown), but not Hispanic women (HR 5 1.16, 95% CI 5 0.82-1.65) had higher EC recurrence risk compared to NHW women. We observed higher EC recurrence among NHB women with low-grade endometrioid (HR 5 2.06, 95% CI 5 1.30-3.27) or carcinosarcoma (HR 5 1.70, 95% CI 5 1.03-2.82) compared to NHW women (Table 2 ). In addition, higher stage was associated with EC recurrence risk across all histologic subtypes, while adjuvant radiation or adjuvant chemotherapy was significantly associated with higher EC recurrence among women with low-grade endometrioid EC. The addition of annual income and education to the multivariable models slightly attenuated estimates for race and EC recurrence: low-grade endometrioid (HR 5 1.94, 95% CI 5 1.21-3.10), and carcinosarcoma (HR 5 1.66, 95% CI 5 0.99-2.79). Neither annual income nor education was significantly associated with EC recurrence in these models, violating criterion three of the Baron-Kenny method. Table 3 shows associations between race and EC recurrence stratified by stage. The higher EC recurrence among NHB compared to NHW women was primarily driven by strong relations for stage I cancers (HR 5 1.57, 95% CI 5 1.14-2.16). The addition of annual income and education slightly attenuated the associations for stage I (HR 5 1.46, 95% CI 5 1.05-2.03). Among women with stage III disease, Hispanic women had an 81% higher risk of EC recurrence compared to NHW women (95% CI 5 1.11-2.95). Neither income nor education was significantly associated with EC recurrence in these models. We did not examine the association between race/ethnicity and EC recurrence in strata defined by both histologic subtype and stage (e.g., low-grade endometrioid and stage I) due to low numbers of events. We conducted several sensitivity analyses. We observed similar associations between race/ethnicity and EC progression (EC recurrence and EC-specific death combined, data not shown). In addition, modeling EC-specific death as a competing event did not materially change our findings. Finally, because recruitment criteria changed in 2007, we evaluated the association between race/ethnicity and EC recurrence separately among women enrolled before and after 2007. Associations were similar in magnitude to the overall model. 
Discussion
Black women have a 93% higher mortality rate after EC diagnosis compared to white women, demonstrating one of the most prominent racial disparities among common cancers. 16 Our analysis extends the literature on racial disparities in EC by demonstrating higher recurrence risk among NHB women diagnosed with low-grade endometrioid, carcinosarcoma or stage I tumors compared to their NHW counterparts, while Hispanic women with stage III disease experienced higher recurrence risk. We did not observe racial differences in recurrence risk for women in subgroups characterized by other tumor characteristics, suggesting some specificity in the association.
Recurrence is an important contributor to death among EC patients. Typically occurring within three years of the initial diagnosis, recurrent ECs are frequently refractory to treatment. 1 As such, surveillance following completion of primary treatment focuses on symptoms of recurrence.
1 Tumor characteristics are the main tools guiding follow-up care based on the perceived risk of recurrence in a specific patient. Broadly speaking, women with early stage or low-grade endometrioid cancers are considered to be at lower risk of recurrence than those with higher-grade and advanced stage disease and thus have less frequent surveillance over time. 1 Our results suggest this surveillance strategy may be inadequate for NHB women perceived to be at a low risk for recurrence.
Several studies have examined racial differences in EC recurrence with inconsistent findings. [5] [6] [7] [8] [9] Two studies reported higher EC recurrence among black women; however, adjustment for tumor characteristics attenuated the association 5, 6 while others have observed significant associations between race and EC recurrence when adjusting for tumor characteristics or restricting to defined subgroups of cases. Among 14 non-Caucasian and 84 Caucasian women with stage IIIA EC, Havrilesky et al. 8 observed a five times higher risk of recurrence among non-Caucasian women in models adjusted for age, BMI, treatment, histology and number of lymph nodes removed. In a study of 44 black and 164 white women with stages I and II EC, Ozen et al. 9 observed a twofold higher recurrence risk among black women in models adjusted for histology. Interestingly, histology was not a predictor of recurrence in this model. In GOG 137, a randomized trial of the effect of estrogen replacement therapy (ERT) vs. placebo on recurrence and overall survival, 17 black women with early stage disease had an 11 times higher EC recurrence compared to white women in the subgroup randomized to receive ERT. 7 The confidence interval reported in this post-hoc analysis of GOG 137 is imprecise, reflective of five recurrences among 59 black EC cases in the ERT arm. 7 Our study agrees with the literature suggesting that NHB women are at higher risk of an EC recurrence. However, our stratification by histology and stage within a large study population allowed us to discern independent associations between race/ethnicity and EC recurrence. Notably, among women with stage I disease or low-grade endometrioid tumors, characteristics indicative of favorable outcomes, NHB experienced higher recurrence risk than NHW women. These findings are likely not attributable to differences in SES or receipt of adjuvant treatment, as we included these potential confounders in our models. Importantly, we only characterized SES along two dimensions, education and income; however, these are commonly accepted SES indicators. 18 In terms of treatment, all women in our study underwent 
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hysterectomy with bilateral oophorectomy; however, adjuvant treatment was prescribed at the discretion of the treating clinician. Adjuvant treatment, an adjustment factor in our analyses, was more frequent among NHB women in the overall study population and among women with stage I tumors, reflective of a greater prevalence of adverse tumor characteristics among NHB women. We speculate that despite stratifying by tumor characteristics and adjusting for treatment, SES and a number of other potential confounders, there is additional heterogeneity in these subgroups that we cannot account for with our data. In particular, we cannot account for racial differences in molecular profiles of stage 1 or low-grade endometrioid tumors that could contribute to the higher recurrence risk among NHB women. To date, the hypothesis that NHB women have molecularly more aggressive tumors has not been borne out by studies investigating differences in global gene expression; 19, 20 however, some have identified racial differences in expression of candidate biomarkers. For example, mutations in TP53 and ERBB2 are more frequent in ECs from black compared to white women, while methylation of ribosomal RNA genes and mutations in PTEN are less prevalent among black as compared to white women, [21] [22] [23] [24] [25] reflecting biologically more aggressive tumors. Whether these alterations differ within stage or histology categories and are independently related to increased EC recurrence risk would need to be examined in a setting with appropriate clinical data, tumor specimens and a large number of EC cases. In addition, there could be racial differences in behaviors following the cancer diagnosis, such as patient adherence to follow-up schedules or changes in lifestyle factors after the cancer diagnosis that could affect recurrence risk.
Several other findings warrant mention. We noted a higher recurrence risk among Hispanic women diagnosed with stage III disease compared to similarly staged NHW women. Again, this observation is unlikely due to differences in SES, treatment, histology or other confounders for which we controlled. More likely, there are unaccounted differences in patient factors that underlie this association. Additional studies examining EC recurrence among Hispanic patients are clearly needed. Also, among women with low-grade endometrioid disease, receipt of adjuvant radiation or chemotherapy was associated with increased recurrence risk. In this subgroup, 16% of women received adjuvant radiotherapy and 4% received adjuvant chemotherapy. According to the National Comprehensive Cancer Network (NCCN), use of adjuvant therapy among women with grade 1 or 2 endometrioid disease is indicated in the presence of adverse risk factors, including age, positive lymphovascular space invasion, tumor size, depth of invasion and lower uterine segment involvement. 26 Although we adjusted for age and stage, our inability to adjust for the other adverse characteristics, due to lack of data, may underlie the increased risk of recurrence associated with receipt of adjuvant therapy among women with low-grade endometrioid EC.
Our study has several strengths including the prospective design, long follow-up, central pathology review and large sample size. Despite the large overall sample size, we were unable to explore race-EC recurrence associations among subgroups cross-classified by stage and histologic subtype. The most clinically relevant ECs are the early-stage, lowgrade endometrioid tumors given their numerical predominance. Although our study included approximately 2,200 women with these characteristics, a small number of recurrences limited our ability to examine this subgroup. Like previous studies, we were unable to examine associations among women of other racial minority groups. Nonetheless, this case-series is one of the largest and includes a diverse array of well-characterized endometrial tumors among NHB, NHW and Hispanic women.
In summary, we observed racial differences in recurrence following an EC diagnosis. Education and income disparities are unlikely to account for these differences, nor are differences in the receipt of treatment. Our results suggest that follow-up care plans should take into account higher EC recurrence risk among NHB women diagnosed with less aggressive tumors (i.e., low-grade endometrioid or stage I tumors). Future studies should also explore the molecular characteristics of recurrent ECs to increase our understanding of the biology and develop biomarkers for risk stratification.
